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Abstract  
Peptide-based vaccines have the potential to overcome the limitations of classical vaccines; 
however, their use is hampered by a lack of carriers and adjuvants suitable for human use. In 
this study, an efficient self-adjuvanting peptide vaccine delivery system was developed based 
on the ionic interactions between cationic trimethyl chitosan (TMC) and a peptide antigen 
coupled with synthetically defined anionic α-poly-(L-glutamic acid) (PGA). The antigen, 
possessing a conserved B-cell epitope derived from the group A streptococcus (GAS) pathogen 
and a universal T-helper epitope, was conjugated to PGA using cycloaddition reaction. The 
produced anionic conjugate formed nanoparticles (NP-1) through interaction with cationic 
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TMC. These NP-1 induced higher systemic and mucosal antibody titers compared to antigen 
adjuvanted with standard mucosal adjuvant cholera toxin B subunit or antigen mixed with 
TMC. The produced serum antibodies were also opsonic against clinically isolated GAS 
strains. Further, a reduction in bacterial burden was observed in nasal secretions, pharyngeal 
surface and nasopharyngeal-associated lymphoid tissue of mice immunized with NP-1 in GAS 
challenge studies. Thus, conjugation of defined-length anionic polymer to peptide antigen as a 
means of formulating ionic interaction-based nanoparticles with cationic polymer is a 
promising strategy for peptide antigen delivery. 
Introduction 
Vaccination is one of the best strategies to control or fight against infectious diseases [1]. 
Traditionally, vaccines were made up of killed or live attenuated bacteria. However, over the 
past few decades, the focus of vaccine development has shifted to subunit vaccines because of 
their improved safety profile and manufacturing advantages compared to their traditional 
counterparts [2]. Peptide subunit vaccines are gaining popularity because they utilize a short, 
defined, synthetic peptide epitope derived from a specific target pathogen to induce well-
defined immune responses without causing adverse effects. They can also be easily chemically 
synthesized in pure state and at large scale [3]. However, these small-sized peptide epitopes 
are poorly immunogenic on their own. They lack danger signals, which are required for their 
recognition by the human immune system [4]. Therefore, immuno-adjuvants or delivery 
systems are always incorporated into peptide vaccines to enhance their immunogenicity [5]. 
Immuno-adjuvants are usually designed based on pathogen-associated molecular patterns 
(PAMP) and are either mixed or formulated with the antigen of interest. Recognition of PAMP 
by receptors present on antigen-presenting cells (APCs) triggers the cascade of immune 
responses [6]. Delivery systems, such as nanoparticles (NPs) and liposomes, are known to 
mimic pathogenic features (e.g. size, shape) and enhance immune response by gaining entry 
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into APCs [7]. NPs built on the conjugation of peptide epitopes and polymers demonstrated 
very promising properties; however, their lack of biodegradability could present a serious 
drawback [8]. Chitosan is a biodegradable, muco-adhesive, non-toxic natural polymer that is 
known to be recognized by mannose receptors, toll-like receptor 2, C-type lectin receptor 
Dectin-1 and leukotriene B4 receptors present on APCs [9, 10]. Chitosan formulations have 
been shown to possess self-adjuvanting properties and improve the immunogenicity of peptide-
based vaccines [11]. Chitosan NPs are usually prepared by charge-charge interactions with an 
anionic crosslinker, antigen or polymer [12, 13]. Previous studies on chitosan NPs for subunit 
vaccine delivery were typically based on the use of anionic tripoly-phosphate (TPP) as a 
crosslinking agent [14]. Safari et al. formulated chitosan-TPP NPs to incorporate commercial 
pneumococcal conjugate vaccine and observed that these NPs induced IgG antibodies 
comparable to those induced by antigen mixed with commercial Quil-A adjuvant [15]. 
Vivanco-Cid et al. recently mixed two protein antigens, bovine serum albumin or E protein 
from dengue virus serotype 2, with chitosan-TPP NPs and showed that these induced primary 
and secondary humoral immune responses comparable to the commercial adjuvant Alum [16]. 
Tian et al. formulated chitosan-based NPs by ionic interactions with anionic ovalbumin (OVA) 
protein antigen, co-loaded with CpG adjuvant [17]. The formulated NPs showed an ability to 
induce both humoral and cellular immunity in mice. Florindo et al. encapsulated or adsorbed 
S. equi M-like protein (SeM) on poly-ɛ-caprolactone/glycol chitosan and poly(L-lactic 
acid)/glycol chitosan NPs [18, 19]. After intranasal immunization in mice, these NPs produced 
a balanced Th1/Th2 immune response. Our group has also previously prepared NPs from 
anionic dextran, poly(lactic-co-glycolic acid) (PLGA) and alginate coated liposomes 
incorporating self-adjuvanting lipopeptide group A streptococcus (GAS) vaccine candidates, 
and further coated these with trimethyl chitosan (TMC) [20, 21]. The coated NPs induced the 
production of high levels of mucosal and systemic antibodies that were opsonic against GAS 
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clinical isolates. Thus, chitosan/TMC NPs can be formulated by ionic interactions, either with 
negatively charged crosslinker, antigen or polymer(s).   
Here, we propose a novel self-adjuvanting vaccine delivery system produced by the 
conjugation of a short length anionic polymer to a peptide antigen in order to form NPs with 
cationic TMC by ionic interactions. To examine this new concept, we conjugated peptide 
antigen to a shorter length synthetic anionic α-poly-(L-glutamic acid) (PGA) polymer. The use 
of synthetically defined PGA to conjugate peptide antigen was expected to offer advantages, 
such as improved NP formulation without the need for crosslinkers. PGA is water-soluble, 
biodegradable, nontoxic, non-immunogenic and clinically tested [22]. It contains numerous 
side chain carboxylic groups available for interaction with cationic TMC.  
GAS is a major pathogen that causes health implications ranging from superficial infection to 
life-threatening rheumatic heart disease. No vaccine is currently available against GAS [23]. 
Thus, a peptide (J8P) possessing conserved B-cell epitope derived from GAS M-protein (J8, 
QAEDKVKQSREAKKQVEKALKQLEDKVQ) and universal T-helper epitope (PADRE, 
AKFVAAWTLKAAA) [24-26] was conjugated to PGA. The GAS peptide antigen coupled 
with PGA (PGA-J8P) was further formulated with cationic TMC without the use of a 
crosslinking agent, lipidation or external adjuvants. This novel vaccine delivery system (NP-
1) was evaluated in vivo to determine its ability to induce humoral immune responses upon 
intranasal administration. Mice immunized with NP-1 generated J8-specific mucosal and 
systemic opsonic antibodies and also showed a reduction in bacterial load in a mucosal GAS 
challenge study.   
2. Experimental 
2.1 Materials  
Protected Fmoc/Boc-amino acids and (1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) were purchased from 
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Mimotopes (Melbourne, Australia). Rink amide p-methylbenzhydrylamine (MBHA) resin was 
purchased from Novabiochem (Hohenbrunn, Germany). p-MBHA·HCl resin was purchased 
from Peptides International (Louisville, USA). N,N’-dimethylformamide (DMF), 
dichloromethane (DCM), methanol, trifluoroacetic acid (TFA), piperidine, HPLC-grade 
acetonitrile and yeast extract were obtained from Merck (Darmstadt, Germany). 4-Pentynoic 
acid was purchased from Alfa Aesar (MA, USA). Methyl iodide and sodium chloride were 
obtained from Chem-Supply (Gilman, SA, Australia). Bovine serum albumin, anti-mouse 
CD16/CD32, PE/CY7-CD11C, BV605-F4/80, BV421-MHC-II, FITC-CD40, PE-CD80 and 
APC-CD86 were obtained from eBioscience (CA, USA). N,N’-diisopropylethylamine 
(DIPEA), triisopropylsilane (TIS), acetic anhydride, 2-azidoacetic acid, copper wire, N-
methyl-2-pyrrolidone (NMP), low molecular weight chitosan (50-190 KDa), sodium iodide, 
erythrocytes lysing buffer, cholera toxin B subunit (CTB), pilocarpine, phosphate buffered 
saline (PBS), phenylmethylsulfonylfluoride (PMSF), antimouse IgG, IgA conjugated to 
horseradish peroxidase and O-phenylenediamine dihydrochloride (OPD) substrate were 
purchased from Sigma-Aldrich (St Louis, USA). Todd-Hewitt broth (THB) was obtained from 
Oxoid and horse blood was purchased from Serum Australis (NSW, Australia). Phenol-free 
IMDM Glutamax medium was obtained from Gibco® Life Technologies (CA, USA).  
2.2 Methods  
2.2.1 Peptide synthesis 
Peptide synthesis was performed on a CEM Discover microwave synthesizer with Synergy 
software. Electrospray ionization mass spectrometry (ESI-MS) was performed on a Shimadzu 
(Kyoto, Japan) instrument with Labsolutions software. Analytical reverse-phase high 
performance liquid chromatography (RP-HPLC) was performed on a Shimadzu instrument 
using a Vydac analytical C18 column (218TP54; 5 µm, 4.6 mm x 250 mm), Solvent A: 0.1% 
TFA in water and Solvent B: 0.1% TFA in acetonitrile:water (90:10), flow rate: 1 mL/min, 
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detection: UV absorbance at 214 nm, method: 0% to 100% linear gradient of solvent B over 
40 min. Preparative RP-HPLC was performed on a Shimadzu instrument using a Vydac or 
Altima preparative C18 column (5 µm, 22 mm x 250 mm) or semi-preparative column (5 µm, 
10 mm x 250 mm), flow rate: 5–20 mL/min, detection: UV absorbance at 214 nm. 1H Nuclear 
magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance 300 MHz 
spectrometer (Bruker Biospin, Germany).  
2.2.1.1 Synthesis of peptide antigen functionalized with alkyne moiety (J8P- alkyne) 
Peptide antigen was synthesized using Boc-chemistry on p-MBHA·HCl resin (substitution 
ratio: 0.59 mmol/g, 0.20 mmol, 0.34 g) by microwave-assisted solid-phase peptide synthesis 
(SPPS). Lysine was used as a linker between PADRE and the J8 sequence. The resin was 
neutralized with DIPEA. Appropriate Boc-protected amino acids (0.84 mmol, 4.2 equiv) were 
pre-activated using HATU (0.50 M, 0.80 mmol, 4.0 equiv, 1.6 mL) and DIPEA (1.2 mmol, 6.2 
equiv, 0.22 mL) 2 min before coupling to the peptide resin. Double coupling was performed 
for 5 and 10 min at 70ºC, 20 W to ensure complete coupling. After the coupling of the first 
amino acid, a capping step was performed using acetic anhydride:DIPEA:DMF (0.5:0.5:9). 
Boc deprotection (1 min) was performed twice using neat TFA. 4-Pentynoic acid was coupled 
to the N-terminus of the peptide. Peptide cleavage from the resin was carried out by treatment 
with hydrofluoric acid (HF) in the presence of p-cresol. The crude cleaved peptide was washed 
with cold ether, filtered, dissolved in acetonitrile:water (50:50) and lyophilized. The obtained 
peptide was purified by preparative HPLC equipped with a C18 column using a gradient of 
30% to 50% of solvent B for 20 min at the flow rate of 20 mL/min. HPLC (C18 column): tR = 
25.2 min, purity > 98%. MW = 4819.64 g/mol. ESI-MS: m/z [M+3H]3+= 1607.7 (calc 1607.5), 
[M+4H]4+ = 1206.1 (calc 1205.9), [M+5H]5+ = 964.9 (calc 964.9), [M+6H]6+ = 804.2 (calc 
804.2), [M+7H]7+ = 689.5 (calc 689.5), [M+8H]8+ = 603.5 (calc 603.4) (see Supporting 
Information Figures S3 and S4); yield: 15%. 
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2.2.1.2 Synthesis of α-polyglutamic acid functionalized with azide moiety (PGA-azide): 
PGA containing ten glutamic acid residues was synthesized by Fmoc-chemistry on rink amide 
MBHA resin (substitution ratio: 0.79 mmol/g, 0.20 mmol, 0.25 g) by microwave-assisted 
SPPS. Fmoc deprotection was performed with 20% piperidine. Fmoc-Glu(OtBu)-OH (0.84 
mmol, 4.2 eq, 0.36 g) was activated with HATU (0.50 M, 0.80 mmol, 4.0 eq, 1.6 mL) and 
DIPEA (1.2 mmol, 5.2 eq, 0.18 mL). Double coupling was performed for 5 and 10 min at 70ºC, 
20 W to ensure complete coupling. 2-Azidoacetic acid was coupled at the N-terminus of PGA. 
PGA-azide was cleaved from the resin using a cocktail of TFA:TIS:water (95:2.5:2.5). The 
obtained PGA-azide was purified by preparative HPLC using a C18 column with a gradient of 
10% to 50% of solvent B for 20 min at a flow rate of 20 mL/min. HPLC (C18 column): tR = 
12.8 min, purity > 95%. MW = 1391.23 g/mol. ESI-MS: m/z [M+H]+ = 1391.7 (calc 1392.2), 
[M+2H]2+ = 696.5 (calc 696.6) (see Supporting Information Figures S5 and S6); yield: 15%. 
2.2.2 Synthesis of polyglutamic acid-peptide conjugate (PGA-J8P) 
Polyglutamic acid-peptide conjugate (PGA-J8P) was synthesized by copper-catalyzed alkyne-
azide cycloaddition (CuAAC) reaction [27]. Briefly, a mixture of PGA-azide (9.3 mmol, 2.0 
eq, 1.3 mg) and J8P-alkyne (4.3 mmol, 1.0 eq, 2.4 mg) was dissolved in 100 µL of DMF. 
Copper wires (60-80 mg) pre-treated with concentrated sulphuric acid for 3 min, washed with 
distilled water and methanol and dried under reduced pressure, were added to the reaction 
mixture. Initially, the air in the reaction mixture was replaced by bubbling nitrogen (15 sec). 
The reaction mixture was protected from light by wrapping the flask with aluminum foil. The 
reaction mixture was stirred at 50°C under nitrogen atmosphere. During the reaction, samples 
(10 µL) were taken hourly and diluted with 60 µL of solvent B. The progress of the reaction 
was monitored by ESI-MS and analytical HPLC analysis (see Supporting Information Figure 
S7). The reaction was completed after 2 h. The blue-to-green-colored reaction mixture was 
diluted with solvent B and purified by preparative HPLC equipped with a C18 column using a 
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gradient of 30% to 90% of solvent B for 30 min at a flow rate of 5 mL/min. HPLC (C18 
column): tR = 24.8 min. MW= 6210.87 g/mol. ESI-MS: m/z [M+5H]5+ = 1243.6 (calc 1243.1), 
[M+6H]6+ = 1036.1 (calc 1036.1), [M+7H]7+ = 888.2 (calc 888.2), [M+8H]8+=777.3 (calc 
777.3), [M+9H]9+ = 692.2 (calc 691.0) (see Supporting Information Figures S8 and S9); yield: 
42%. 
2.2.3 Synthesis of N-trimethyl chitosan (TMC)  
TMC was prepared following a previously reported method [28, 29]. Further information on 
the synthesis can be found in the supplementary information. 
2.2.4 Preparation of NP-1 
A solution of PGA-J8P (0.6 mg/mL) was prepared in endotoxin free water. TMC (2 mg/mL) 
was added drop-wise to the PGA-J8P aqueous solution over 30 min with stirring at room 
temperature to form NP-1. The PGA-J8P aqueous solution was titrated with different weight 
ratios of TMC. Surface coating with TMC was verified by monitoring the size and 
polydispersity index (PDI) of NP-1 during the coating process (Figure 2).  
2.2.5 Characterization of NP-1 (particle size, ζ-potential and morphology) 
The size and ζ-potential of NP-1 were measured in endotoxin free water by dynamic light 
scattering (DLS) using a Zetasizer (Nano Series ZS, Malvern Instruments, UK) at 25°C in 
folded capillary cuvettes. The measurements were taken with a back scattering angle of 173°. 
The average size of the particles was calculated by the Zetasizer 6.2 software (Malvern 
Instruments, UK). The morphology of NP-1 was visualized by transmission electron 
microscopy (TEM; HT7700 Exalens, HITACHI Ltd., Japan) operating at a voltage of 120 kV. 
The carbon-coated copper grids (Ted Pella, 200 mesh) were glow discharged for 15 sec and 5 
µL of sample was mounted. The particles were allowed to deposit on the grid for 2 min. Excess 
formulation was wicked off with Whatman filter paper and particles were stained with 2% 
phosphotungstic acid for 30 sec. Excess staining solution was wicked off with Whatman filter 
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paper, and the grids were air-dried for 5 min in clean conditions before being loaded onto the 
microscope for viewing.  
2.2.6 In vitro DCs and macrophages maturation study 
Spleens from C57/BL6 mice were passed through a 70 µm cell strainer to obtain single cell 
suspension of splenocytes in cold complete media (phenol-free IMDM Glutamax medium 
supplemented with streptomycin (100 μg/mL), penicillin (100 IU/mL), 2-mercaptoethanol (50 
μM) and 10% fetal bovine serum). Red blood cells lysis was performed by the addition of 1 
mL of erythrocyte lysing buffer followed by incubation on ice for 7 min. Cells were introduced 
into a 96-well plate at a density of 1 × 106 cells/well and incubated at 37°C for 2 h. NP-1, PGA-
J8P, J8P/CTB and J8P/TMC mixtures were added to each well in 25 µM concentration and 
incubated at 37°C overnight. Cells adhering to the plates were scraped and centrifuged at 350 
g for 5 min. The supernatant was discarded, and the cells were incubated for 10 min at 4°C 
with 50 µL anti-mouse CD16/CD32 diluted (1:1000 v/v) in FACS buffer (1xPBS, 0.02% 
sodium azide, 0.5% bovine serum albumin). The plates were centrifuged at 350 g for 5 min, 
the supernatant was discarded and the cells were incubated with 50 µL of antibody cocktail 
(PE/CY7-CD11C, BV605-F4/80, BV421-MHC-II, FITC-CD40, PE-CD80 and APC-CD86) 
for 30 min at 4°C in the dark. Cells were then washed three times with increasing amounts of 
FACS buffer (100 µL, 150 µL and 200 µL). Fixation buffer (50 µL) was added into each well 
and the cells were incubated for 20 min at room temperature. The wells were then topped up 
with 150 µL FACS buffer and centrifuged at 400 g for 5 min. The supernatant was discarded 
and the contents were diluted with 300 µL FACS buffer in a polystyrene flow cytometry sterile 
test tube. The cells were kept in dark conditions at 4°C until analyzed using a BD LSRII flow 
cytometer (BD Biosciences, CA, USA). 
2.2.7 In-vivo murine study 
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All animal protocols were approved by the Griffith University Research Ethics Review Board 
(GU Ref No. GLY-01-15-AEC) in accordance with Australian National Health and Medical 
Research Council (NHMRC) guidelines. Six-week old female inbred C57/BL6 mice obtained 
from the Animal Resource Centre (Perth, Western Australia) were divided into five groups of 
10 mice each. Negative control mice were intranasally administered with PBS (10 µL/nare), 
while positive control mice received an intranasal physical mixture of J8P and CTB (10 µg 
each) in 20 µL of water. Other groups were administered with NP-1 (containing 10 µg of J8P), 
J8P peptide alone (10 µg) or a physical mixture of J8P/TMC (10 µg of J8P) in 20 µL water (10 
µL/nare). All mice were intranasally immunized on day 0, followed by boosts on days 21 and 
42.  
2.2.8 Sample collection 
Serum samples were collected on days 20, 41 and 55 post primary immunization to determine 
the level of J8-specific IgG antibodies. Blood (10 µL) collected via tail snip was added to PBS 
(90 µL) and centrifuged at 4000 g for 10 min to collect sera. Clear supernatant was stored at -
20ºC for further analysis. Saliva was collected on days 6, 27 and 48 post primary immunization 
to determine the level of J8-specific IgA antibodies. Mice were given 50 µL of 0.1% 
pilocarpine intraperitoneally (i.p.) and left for 2 min before collecting saliva. Collected saliva 
was added to 1 µL of PMSF, a protease inhibitor solution, and stored at -80ºC for further 
analysis. 
2.2.9 Determination of antibody titers  
To determine J8-specific IgG and IgA antibody titers, enzyme-linked immunosorbent assays 
(ELISA) were performed [30]. Flat bottom 96-well plates were coated with J8 peptide (5 
µg/well) and blocked with 5% skim milk. Two-fold serial dilutions were performed for serum 
IgG (1:200) and salivary antibodies (1:4). Horseradish peroxidase conjugated secondary 
antibody (IgG or IgA) was added to the plate and color development was observed after adding 
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OPD substrate. Optical density was measured at 450 nm using a microplate reader (Molecular 
Devices, CA, USA). Antibody titers were determined by the lowest dilution showing an optical 
density greater than the average + 3 standard deviations (SD) of control wells (sera/saliva from 
the negative control group). The data were statistically analyzed by one-way ANOVA followed 
by Tukey post-hoc test.  
2.2.10 Intranasal GAS challenge study 
Mice were challenged 20 days after the second boost with a dose of 5 × 106 colony-forming 
unit (CFU)/10 µL streptomycin-resistant M1 GAS strain, which was serially passaged in mouse 
spleen to enhance virulence [31]. Twenty-four hours prior to intranasal challenge with GAS, 
streptomycin (200 µg/mL) was included in mouse drinking water. On the day of challenge, 
mice were anaesthetized with an i.p. injection of 75-100 µL of Ketamine:Xylazine (1:1) 
dissolved in 10 mL of water, and challenged with the bacterial sample (10 µL/mouse). Mice 
were laid on their back, nose facing upward, to encourage ingestion of the bacteria. One mouse 
from the positive control group died prior to bacterial challenge. 
2.2.11 Nasal shedding, throat swabs and nasal associated lymphoid tissue 
Nares of each mouse were pressed ten times (on days 1 and 2 post-challenge) onto the surface 
of Columbia blood agar (CBA) plates containing 2% defibrinated horse blood with 200 µg/mL 
streptomycin. The plates were cultured in duplicate for each mouse. The plates were streaked 
out and incubated overnight at 37°C. Mouse throats were swabbed using a sterile Minitip Flaq 
Swab (COPAN Diagnostics, Corona, CA, USA) moistened with sterile PBS on days 1 and 2 
post-challenge. The throat swabs were also cultured on CBA plates containing 2% defibrinated 
horse blood and 200 µg/mL streptomycin and incubated overnight at 37°C. On day 3 post-
challenge, mice were culled by CO2 asphyxiation. Nasal associated lymphoid tissue (NALT) 
samples were collected in sterile PBS containing 15 mM EDTA and homogenized in a bullet-
blender homogenizer. Subsequently, NALT samples were serially diluted from 10-1 to 10-3 and 
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20 µL was plated on CBA plates in duplicate using the pour plate method. The plates were 
incubated overnight at 37°C. All plates were stored at 4ºC until individual hemolytic GAS 
colonies were counted. 
2.2.12 Opsonization assay  
The sera of mice collected on 13 days after the second boost were tested in an indirect 
bactericidal assay to evaluate the opsonic ability of serum IgG antibodies against various GAS 
strains [21]. The clinical isolates examined in this assay were ACM-5199 (ATCC 12344, NCIB 
11841, scarlet fever); ACM-5203 (ATCC 19615, pharynx of child following the episode of 
sore throat); GC2 203 (wound swab); D3840 (nasopharynx swab); and D2612 (nasopharynx 
swab). Bacteria were plated on THB plates supplemented with 5% yeast extract and incubated 
at 37°C for 24 h. A single colony from each bacterium was transferred to 5 mL of THB supple-
mented with 5% yeast extract and incubated for 24 h at 37°C to obtain approximately 4-5 × 106 
CFU/mL. Cultures were serially diluted to 10-2 in PBS. Aliquots (10 μL) were mixed with 20 
μL of heat-inactivated sera and 80 μL of horse blood, and incubated in 96-well plates at 37°C 
for 3 h. Sera were inactivated by heating in a water bath at 50°C for 30 min. Aliquots (10 μL) 
from the 96-well plate were then plated on THB plates supplemented with 5% yeast extract 
containing 5% horse blood. Plates were incubated at 37°C for 24 h and bacterial survival was 
analyzed by enumerating CFU. Opsonic activity of the antibodies (anti-peptide) sera (% 
reduction in mean CFU) was calculated as [1-(CFU in the presence of anti-peptide sera)/(mean 
CFU in the presence of sera from negative control group)] × 100 [32]. The assay was performed 
in triplicate from three independent cultures. 
3. Results 
3.1 Synthesis of PGA-J8P and TMC 
A copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition “click” reaction was employed to 
conjugate PGA to the J8P peptide (Figure 1) [27]. Firstly, peptides possessing J8 and PADRE 
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sequences (J8P) were synthesized by Boc-SPPS. 4-Pentynoic acid was coupled to the N- 
terminus of the peptide to functionalize it with the alkyne moiety (J8P-alkyne). PGA was 
synthesized using Fmoc-SPPS and modified with 2-azidoacetic acid on its N-terminus (PGA-
azide). The J8P-alkyne and PGA-azide were then conjugated via CuAAC reaction using Cu 
wires in DMF [28, 29]. Two equivalents of PGA-azide were used to ensure the complete 
consumption of J8P-alkyne. The reaction was monitored by ESI-MS and HPLC, and was 
completed in 2-3 h. 
 
Figure 1. Schematic illustration of the synthetic procedure for PGA-J8P (A) and TMC (B). 
  
14 
 
TMC was produced by methylation of chitosan using methyl iodide under alkaline conditions 
by the two-step method [28]. It was observed that the degree of trimethylation was relatively 
low (<50%) after completion of single methylation. The water solubility of TMC is highly 
dependent on the degree of methylation; thus, a higher level of trimethylation was desired [33]. 
When double methylation was performed, 74% of the amine groups of chitosan were 
substituted with trimethyl groups and 16% with dimethyl groups. The degree of N-acetylation 
was 10%. 
3.2 Formulation optimization of NP-1 
NP-1 were prepared by the ionic interactions of cationic TMC with anionic PGA-J8P peptide 
antigen (Figure 2A). Aqueous TMC solution was added dropwise into an aqueous solution of 
PGA-J8P under magnetic stirring at room temperature, enabling the formation of NPs over a 
period of time without using high-energy forces. The formation of NP-1 was monitored by 
DLS (see Supporting Information Table 1 and Figure S11). Figure 2B summarizes the changes 
in particle size and PDI at different weight ratios of PGA-J8P/TMC.  
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Figure 2. Schematic illustration and characterization of NP-1. (A) Schematic illustration of the preparation of 
NP-1. (B) Overview of the change in size and PDI of NP-1. Data is represented as mean ± SD. (C) TEM image 
of NP-1 formed by 1:1 w/w of PGA-J8P to TMC (scale bar = 500 nm). 
The NP-1 formed using equal weight ratios of PGA-J8P to TMC (1:1 w/w) possessed the 
lowest particle size (201 ± 8 nm) with a PDI of 0.33. The further addition of TMC (up to 2 
w/w) increased both the particle size and PDI. Hence, NP-1 formed using equal weight ratios 
of PGA-J8P/TMC were chosen for in vivo murine study. These NP-1 were morphologically 
characterized by TEM (Figure 2C). TEM images of the PGA-J8P/TMC confirmed the 
formation of NP-1 with similar sizes to those detected by DLS (see Supporting Information 
Figures S12 and S13).  
3.3 In vitro DCs and macrophages maturation study 
The ability of NP-1 to induce the maturation of dendritic cells (DCs) and macrophages was 
evaluated in vitro using murine splenic CD11c+ dendritic cells and F4/80+ macrophages. 
Splenic cells were cultured with negative control PBS, positive control J8P/CTB mixture, NP-
1, PGA-J8P alone and J8P/TMC mixture in triplicate in a concentration of 25 µM peptide. The 
expression of maturation markers was measured by flow cytometry. NP-1 and the J8P/CTB 
mixture were more effective in stimulating MHC-II and CD80 in both DCs and macrophages, 
compared to negative control (Figure 3). NP-1 induced higher expression of MHC-II in DCs 
and macrophages, compared to soluble PGA-J8P and J8P/TMC mixture (p < 0.001).   
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Figure 3. Expression of MHC-II and CD80 on the surface of CD11c+ DCs and F4/80+ macrophages as analyzed 
by flow cytometry (n = 3). (A) Mean fluorescence intensity of isolated CD11c+ dendritic cells and F4/80+ 
macrophages for MHC-II expression. (B) Mean fluorescence intensity of isolated CD11c+ dendritic cells and 
F4/80+ macrophages for CD80 expression. Data is represented as mean ± SD. Statistical analysis was performed 
using two-way ANOVA followed by Tukey’s multiple comparison test. Not significant (ns), p > 0.05; *, p < 0.05; 
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
3.4 Immunogenicity of NP-1 
Ten mice in each group were intranasally administered with NP-1, PGA-J8P alone or physical 
mixtures of J8P with TMC. Negative control mice received PBS, whereas positive control mice 
received a physical mixture of J8P with commercial mucosal adjuvant CTB. All groups 
received the same concentrations of J8P (10 µg/mouse) in 20 µL water. The serum IgG and 
salivary IgA antibody titers obtained on day 55 post-primary immunization are shown in Figure 
4. It was observed that NP-1 induced higher levels of J8-specific serum IgG and salivary IgA 
compared to PBS and other groups. When a low dose of J8-based antigen (10 µg/mouse) mixed 
with commercial adjuvant CTB was administered to mice, the IgA antibody titers were 
significantly lower compared to those produced by mice immunized with the same amount of 
the antigen in the form of NP-1. Additionally, mice administered with PGA-J8P alone or 
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J8P/TMC physical mixture showed significantly lower IgG and IgA titers than mice that 
received NP-1. 
 
Figure 4. J8-specific antibody responses post-intranasal administration of vaccine NP-1 and controls in C57/BL6 
mice (n=10), as determined by ELISA. (A) J8-specific serum IgG titers. (B) J8-specific salivary IgA titers. 
Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test to 
compare test groups against PBS or NP-1, as indicated. Not significant (ns), p > 0.05; *, p < 0.05; **, p <0.01; 
***, p < 0.001; ****, p < 0.0001). GraphPad Prism version 7.03 was used to perform statistical analyses.  
3.5 Protection against GAS infection 
To determine protection against GAS, mice immunized with PBS, J8P/CTB mixture, NP-1, 
PGA-J8P and J8P/TMC mixture were intranasally challenged with the M1 GAS strain. The 
challenge study clearly demonstrated the capacity of the developed nanoparticulate system 
(NP-1) to trigger protection against GAS infection. Post-challenge, the bacterial load in nasal 
discharge was significantly lower on day 2 in mice immunized with NP-1 compared to mice 
that had received PBS (Figure 5A). Mice that received NP-1 also showed reduced bacterial 
load in NALT, as well as on the pharyngeal surface (throat swabs) (Figure 5B and C). Physical 
mixtures J8P/CTB and J8P/TMC, and soluble PGA-J8P failed to protect mice against the M1 
GAS strain. 
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Figure 5. Bacterial burden in nasal shedding (A), throat swabs (B) and NALT (C) following intranasal challenge 
with the M1 GAS strain in C57/BL6 mice (n = 10/group). The results are represented as the mean CFU + standard 
error of the mean (SEM). Statistical analyses for throat swabs were performed by repeated measures (RM) two-
way ANOVA followed by Tukey’s multiple comparisons test, whereas statistical analyses for nasal shedding and 
NALT were performed by ordinary two-way ANOVA followed by Tukey’s multiple comparisons test to compare 
test groups against PBS. (D) Opsonization of various GAS strains by serum antibodies produced in mice 
administered with NP-1 and PBS. The average percentage of opsonization for each group is shown with SEM 
bars. Statistical analyses were performed using two-way ANOVA followed by Sidak’s multiple comparisons test 
to compare against the PBS group. Not significant (ns), p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001, ****, 
p < 0.0001). GraphPad Prism version 7.03 was used to perform statistical analyses. 
3.6 Induction of opsonic antibodies against various GAS strains 
To determine whether the serum antibodies from mice immunized with NP-1 also possess 
opsonization activity against other GAS strains, an in vitro bactericidal assay was performed 
against five GAS clinical isolates D2612, D3840, GC2 203, ACM-5203 and ACM-5199. The 
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J8-specific antibodies produced in the sera of mice immunized with NP-1 showed significant 
opsonic activity against all tested clinical isolates (Figure 5D).  
4. Discussion 
The GAS pathogen invades the human body mainly through mucosal surfaces of the upper 
respiratory tract [23]. Immunization via mucosal routes to prevent colonization and systemic 
invasion is the preferred approach for the prevention of infections. To develop a mucosal 
vaccine, we selected chitosan as a delivery platform because of its excellent muco-adhesive 
properties [34]. Chitosan was reported to be responsible for antigen retention in nasal passages 
and the opening of tight epithelial junctions, promoting paracellular transport of antigens [9]. 
The mucosal adhesivity of chitosan is based on ionic interactions between the cationic amine 
group of the polymer and the negatively charged residues present in mucus [35]. However, 
chitosan (pKa ~6.5) possesses a positive charge and is water-soluble only at an acidic pH. 
Therefore, the agglomeration of chitosan formulations at physiological pH is a common 
problem that dictates the need for water-soluble chitosan derivatives [36]. However, chitosan’s 
trimethylated derivative possesses a permanent cationic charge, is water-soluble over a wide 
pH range, and demonstrated stronger mucoadhesion, enhanced membrane permeation and 
absorption at neutral pH [37, 38]. Thus, we methylated the chitosan amine groups with methyl 
iodide to produce TMC with a high degree of quaternization (74%). 
Chitosan/TMC NPs have mostly been formulated by ionic interactions with counter-ions in the 
form of either crosslinkers, such as TPP, or anionic polymers, such as alginate, dextran or γ-
PGA [15-17, 21]. However, crosslinkers may lead to changes in conformation or antigenic 
properties of the peptide epitope [39], while the use of anionic polymers could lead to an 
increase in particle size [20]. The formulation of chitosan NPs can be achieved without 
crosslinkers using the supercritical enhanced atomization spray drying technique [40]. In 
contrast, we developed a novel simple vaccine delivery strategy by modifying the peptide 
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antigen itself with defined poly-ions that can further interact with an oppositely charged 
polymer of interest. To develop cationic NP-1, we conjugated a GAS peptide antigen with short 
polyanionic PGA via copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction. 
Conjugation rendered a negative charge on the peptide antigen, which enabled the formation 
of NPs with cationic TMC without the use of any external crosslinker. PGA was specifically 
chosen for conjugation due to its highly anionic nature, similar to polyphosphate crosslinkers. 
PGA is hydrophilic, fully biodegradable, biocompatible and easy to synthesize in pure state by 
SPPS [41]. 
The peptide-PGA conjugate, when mixed with cationic TMC, formed NP-1. It has been shown 
that NPs 50-200 nm in size are effectively taken up by M-cells and internalized in dendritic 
cells by receptor-mediated endocytosis [42]. Hence, the mixing of TMC with peptide-PGA 
conjugate was performed until NP-1 reached 200 nm (measured by DLS). The size of NP-1 
was further confirmed with TEM (Figure 2). Surface charge also plays an important role in the 
presentation of NPs to underlying APCs and the immune stimulation of dendritic cells [43]. It 
is well-reported that positively charged particles can gain access to APCs, considering 
electrostatic interaction with negatively charged cell membranes [44]. Thus, NP-1 were 
formulated in such a manner to achieve a positive ζ-potential value (+36 mV).  
Mature APCs play a vital role in the regulation and amplification of immune responses against 
infectious pathogens [45, 46].  Maturation of DCs and macrophages involves up-regulation of 
MHC-II expression, which is responsible for antigen presentation to CD4+ T cells and other 
co-stimulatory molecules, such as CD80 [47]. All tested groups induced expression of MHC-
II and CD80 in both DCs and macrophages (Figure 3); however, only positive control 
(J8P/CTB mixture) and NP-1 induced statistically significant overexpression of these markers 
compared to PBS (p < 0.0001). Interestingly, TMC delivered in simple mixture with antigen 
(J8P) triggered significantly weaker expression of maturation markers than TMC in the form 
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of NPs (NP-1). Indeed, TMC in NP form was previously reported to induce higher expression 
of maturation markers compared to TMC/antigen mixture [48]; likewise, non-formulated 
chitosan was also found to be a poor or non-inducer of maturation markers [49].  
To confirm that NP-1 are able to not only stimulate maturation of APCs, but also trigger antigen 
specific adaptive immunity, their immunostimulating potential was evaluated through an in 
vivo immunization study. On intranasal administration to mice, NP-1 induced significantly 
higher serum IgG and mucosal IgA antibody titers against J8 compared to all other tested 
groups (Figure 4). The physical mixture J8P/CTB produced lower IgA antibody titers 
compared to NP-1, which indicates superiority of NP-1 over the commercial adjuvant CTB. 
The presence of TMC in NP-1 was necessary for a strong humoral immune response. Weak 
IgG and IgA titers were obtained upon the administration of soluble PGA-J8P, indicating an 
adjuvanting property of TMC. The formation of ionic interaction-based NP-1 was also crucial 
for the induction of better systemic and mucosal immune responses since the simple physical 
mixture of J8P with TMC triggered significantly lower IgG and IgA production.  
Before systemic invasion into a host, the GAS pathogen readily colonizes mucosal tissues in 
the nasopharynx and respiratory tract [50]. To determine if NP-1 are effective against bacterial 
infection through nasopharyngeal mucosal surfaces, a murine challenge model was employed 
by intranasally administering the M1 GAS strain. A significantly reduced bacterial load was 
observed from nasal shedding of mice vaccinated with NP-1 compared to PBS-treated mice on 
day 2 (Figure 5A). The bacterial burden was also significantly reduced in the throats and NALT 
of mice vaccinated with NP-1 compared to those that received PBS (Figure 5B and 4C). Peptide 
antigen J8P administered with commercial mucosal adjuvant CTB, soluble PGA-J8P or 
physical J8P/TMC mixture were ineffective in providing protection to mice against GAS 
infection. The lack of protection in mice treated with commercial adjuvant can be explained by 
the relatively poor antibody response triggered by CTB at the tested antigen concentration. 
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Thus, the ability of antigen formulation (e.g. CTB-based) to trigger maturation of APCs is a 
necessary but not a sufficient factor for the vaccine efficacy. The effectiveness of a vaccine is 
also related to the capacity of generated antibodies to opsonize various strains of the bacteria. 
An indirect bactericidal assay indicated that serum antibodies produced in mice immunized 
with NP-1 were effective not only against the M1 GAS strain, but also against a variety of 
clinical isolates (Figure 5D). Overall, NP-1, even at low antigen concentration compared to 
previous reports [30, 51-53], induced high IgA and opsonic IgG antibody titers and showed 
protection against GAS infection.  
5. Conclusion 
The use of synthetically defined PGA greatly enhanced NPs formulation with no external 
crosslinker. This shows that PGA may not only act as a complexing agent, but potentially also 
as a crosslinker similar to polyphosphate. Additionally, conjugation of PGA to the peptide 
antigen rendered negative charge on the antigenic peptide, which allowed formation of NPs 
with cationic TMC by ionic interaction. This strategy is very effective when a positively 
charged formulation is desired for neutral or cationic peptide antigens without any anionic 
polymer coating or additional crosslinker. The developed nanoparticulate peptide vaccine (NP-
1) improved the immunogenicity of J8P antigen without any lipidation, suggesting a self-
adjuvanting property of this delivery system. Thus, the modification of peptide antigen with 
PGA followed by the formation of cationic NPs with TMC is a highly promising strategy for 
peptide antigen delivery.  
Supporting information: Mass spectra and HPLC chromatograms for J8P, J8P-alkyne, PGA-
azide and PGA-J8P, CuAAC reaction monitoring by HPLC and size measurement of NP-1 by 
DLS. 
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Statement of significance 
A self-adjuvanting delivery system is required for peptide vaccines to enhance antigen delivery 
to immune cells and generate systemic and mucosal immunity. Herein, we developed a novel 
self-adjuvanting nanoparticulate delivery system for peptide antigens by combining polymer-
conjugation and complexation strategies. We conjugated peptide antigen with anionic α-poly-
(L-glutamic acid) that in turn, formed nanoparticles with cationic trimethyl chitosan by ionic 
interactions, without using external crosslinker. On intranasal administration to mice, these 
nanoparticles induced systemic and mucosal immunity, at low dose. Additionally, 
nanoparticles provided protection to vaccinated mice against group A streptococcus infection. 
Thus, this concept should be particularly useful in developing nanoparticles for the delivery of 
peptide antigens. 
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